An important goal of this study is to evaluate the length of time cancer is not growing or spreading in participants when treated with zanzalintinib compared to everolimus. In addition, this study will also evaluate if zanzalintinib can shrink tumors and help participants live longer as compared to everolimus. This information will help researchers learn if zanzalintinib can be used to treat neuroendocrine cancer.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Jonathan Sorah
Medicine- Oncology
Clinical or Medical
Interventional
Cancer (Liver, Pancreatic)
Kidneys and Liver
25-1455
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
